CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.

Abstract

The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.

• Authors: Yongxian Hu, Elaine Tan Su Yin, Yingying Yang, Hengwei Wu, Guoqing Wei, Junwei Su, Qu Cui, Aiyun Jin, Li Yang, Shan Fu, Jianfeng Zhou, Lugui Qiu, Xi Zhang, Aibin Liang, Hongmei Jing, Yuhua Li, Didier Blaise, Mohamad Mohty, Arnon Nagler, He Huang
• Journal: Current research in translational medicine (Curr Res Transl Med) Vol. 68 Issue 3 Pg. 111-118 (08 2020) ISSN: 2452-3186 [Electronic] France
• PMID: 32620465 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Chemical References

• Receptors, Antigen, T-Cell

Topics

• Betacoronavirus (physiology)
• COVID-19
• Coronavirus Infections (epidemiology, prevention & control)
• Delivery of Health Care (methods, organization & administration, standards, trends)
• Hematologic Neoplasms (epidemiology, therapy)
• Humans
• Immunotherapy, Adoptive (methods, trends)
• Infection Control (methods, organization & administration, standards, trends)
• Pandemics (prevention & control)
• Pneumonia, Viral (epidemiology, prevention & control)
• Preventive Health Services (methods, organization & administration, standards, trends)
• Receptors, Antigen, T-Cell (immunology)
• SARS-CoV-2